Efficacy of vaccination against HPV infections to prevent cervical cancer in France: present assessment and pathways to improve vaccination policies.

BACKGROUND: Seventy percent of sexually active individuals will be infected with Human Papillomavirus (HPV) during their lifetime. These infections are incriminated for almost all cervical cancers. In France, 3,068 new cases of cervical cancer and 1,067 deaths from cervical cancer occurred in 2005....

Full description

Bibliographic Details
Main Authors: Laureen Ribassin-Majed, Rachid Lounes, Stephan Clémençon
Format: Article
Language:English
Published: Public Library of Science (PLoS) 2012-01-01
Series:PLoS ONE
Online Access:http://europepmc.org/articles/PMC3299653?pdf=render
id doaj-c476435eb502426e89d89c2f03e5758a
record_format Article
spelling doaj-c476435eb502426e89d89c2f03e5758a2020-11-25T01:53:27ZengPublic Library of Science (PLoS)PLoS ONE1932-62032012-01-0173e3225110.1371/journal.pone.0032251Efficacy of vaccination against HPV infections to prevent cervical cancer in France: present assessment and pathways to improve vaccination policies.Laureen Ribassin-MajedRachid LounesStephan ClémençonBACKGROUND: Seventy percent of sexually active individuals will be infected with Human Papillomavirus (HPV) during their lifetime. These infections are incriminated for almost all cervical cancers. In France, 3,068 new cases of cervical cancer and 1,067 deaths from cervical cancer occurred in 2005. Two vaccines against HPV infections are currently available and vaccination policies aim to decrease the incidence of HPV infections and of cervical cancers. In France, vaccine coverage has been reported to be low. METHODS: We developed a dynamic model for the heterosexual transmission of Human Papillomavirus types 16 and 18, which are covered by available vaccines. A deterministic model was used with stratification on gender, age and sexual behavior. Immunity obtained from vaccination was taken into account. The model was calibrated using French data of cervical cancer incidence. RESULTS: In view of current vaccine coverage and screening, we expected a 32% and 83% reduction in the incidence of cervical cancers due to HPV 16/18, after 20 years and 50 years of vaccine introduction respectively. Vaccine coverage and screening rates were assumed to be constant. However, increasing vaccine coverage in women or vaccinating girls before 14 showed a better impact on cervical cancer incidence. On the other hand, performing vaccination in men improves the effect on cervical cancer incidence only moderately, compared to strategies in females only. CONCLUSION: While current vaccination policies may significantly decrease cervical cancer incidence, other supplementary strategies in females could be considered in order to improve vaccination efficacy.http://europepmc.org/articles/PMC3299653?pdf=render
collection DOAJ
language English
format Article
sources DOAJ
author Laureen Ribassin-Majed
Rachid Lounes
Stephan Clémençon
spellingShingle Laureen Ribassin-Majed
Rachid Lounes
Stephan Clémençon
Efficacy of vaccination against HPV infections to prevent cervical cancer in France: present assessment and pathways to improve vaccination policies.
PLoS ONE
author_facet Laureen Ribassin-Majed
Rachid Lounes
Stephan Clémençon
author_sort Laureen Ribassin-Majed
title Efficacy of vaccination against HPV infections to prevent cervical cancer in France: present assessment and pathways to improve vaccination policies.
title_short Efficacy of vaccination against HPV infections to prevent cervical cancer in France: present assessment and pathways to improve vaccination policies.
title_full Efficacy of vaccination against HPV infections to prevent cervical cancer in France: present assessment and pathways to improve vaccination policies.
title_fullStr Efficacy of vaccination against HPV infections to prevent cervical cancer in France: present assessment and pathways to improve vaccination policies.
title_full_unstemmed Efficacy of vaccination against HPV infections to prevent cervical cancer in France: present assessment and pathways to improve vaccination policies.
title_sort efficacy of vaccination against hpv infections to prevent cervical cancer in france: present assessment and pathways to improve vaccination policies.
publisher Public Library of Science (PLoS)
series PLoS ONE
issn 1932-6203
publishDate 2012-01-01
description BACKGROUND: Seventy percent of sexually active individuals will be infected with Human Papillomavirus (HPV) during their lifetime. These infections are incriminated for almost all cervical cancers. In France, 3,068 new cases of cervical cancer and 1,067 deaths from cervical cancer occurred in 2005. Two vaccines against HPV infections are currently available and vaccination policies aim to decrease the incidence of HPV infections and of cervical cancers. In France, vaccine coverage has been reported to be low. METHODS: We developed a dynamic model for the heterosexual transmission of Human Papillomavirus types 16 and 18, which are covered by available vaccines. A deterministic model was used with stratification on gender, age and sexual behavior. Immunity obtained from vaccination was taken into account. The model was calibrated using French data of cervical cancer incidence. RESULTS: In view of current vaccine coverage and screening, we expected a 32% and 83% reduction in the incidence of cervical cancers due to HPV 16/18, after 20 years and 50 years of vaccine introduction respectively. Vaccine coverage and screening rates were assumed to be constant. However, increasing vaccine coverage in women or vaccinating girls before 14 showed a better impact on cervical cancer incidence. On the other hand, performing vaccination in men improves the effect on cervical cancer incidence only moderately, compared to strategies in females only. CONCLUSION: While current vaccination policies may significantly decrease cervical cancer incidence, other supplementary strategies in females could be considered in order to improve vaccination efficacy.
url http://europepmc.org/articles/PMC3299653?pdf=render
work_keys_str_mv AT laureenribassinmajed efficacyofvaccinationagainsthpvinfectionstopreventcervicalcancerinfrancepresentassessmentandpathwaystoimprovevaccinationpolicies
AT rachidlounes efficacyofvaccinationagainsthpvinfectionstopreventcervicalcancerinfrancepresentassessmentandpathwaystoimprovevaccinationpolicies
AT stephanclemencon efficacyofvaccinationagainsthpvinfectionstopreventcervicalcancerinfrancepresentassessmentandpathwaystoimprovevaccinationpolicies
_version_ 1724990865431068672